Van der Born K - Search Results

1

Role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity.

de Bruin M, van Capel T, Van der Born K, Kruyt FA, Fukushima M, Hoekman K, Pinedo HM, Peters GJ. de Bruin M, et al. Among authors: van capel t, van der born k. Br J Cancer. 2003 Mar 24;88(6):957-64. doi: 10.1038/sj.bjc.6600808. Br J Cancer. 2003. PMID: 12644837 Free PMC article.

2

Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells.

Temmink OH, Hoebe EK, van der Born K, Ackland SP, Fukushima M, Peters GJ. Temmink OH, et al. Among authors: van der born k. Br J Cancer. 2007 Jan 29;96(2):231-40. doi: 10.1038/sj.bjc.6603549. Br J Cancer. 2007. PMID: 17242697 Free PMC article.

3

Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1-phosphate.

de Bruin M, van Capel T, Smid K, van der Born K, Fukushima M, Hoekman K, Pinedo HM, Peters GJ. de Bruin M, et al. Among authors: van der born k. Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1485-90. doi: 10.1081/NCN-200027702. Nucleosides Nucleotides Nucleic Acids. 2004. PMID: 15571282

4

Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.

Kroep JR, Smit EF, Giaccone G, Van der Born K, Beijnen JH, Van Groeningen CJ, Van der Vijgh WJ, Postmus PE, Pinedo HM, Peters GJ. Kroep JR, et al. Among authors: van der born k. Cancer Chemother Pharmacol. 2006 Oct;58(4):509-16. doi: 10.1007/s00280-006-0191-z. Epub 2006 Mar 7. Cancer Chemother Pharmacol. 2006. PMID: 16523337 Clinical Trial.

5

Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.

Adema AD, van der Born K, Honeywell RJ, Peters GJ. Adema AD, et al. Among authors: van der born k. J Chemother. 2009 Jun;21(3):338-46. doi: 10.1179/joc.2009.21.3.338. J Chemother. 2009. PMID: 19567356

6

Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung.

Wittgen BP, Kunst PW, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, Perez-Soler R, Nicholson S, Peters GJ, Postmus PE. Wittgen BP, et al. Among authors: van der born k. Clin Cancer Res. 2007 Apr 15;13(8):2414-21. doi: 10.1158/1078-0432.CCR-06-1480. Clin Cancer Res. 2007. PMID: 17438100 Free article. Clinical Trial.

7

No evidence of gemcitabine accumulation during weekly administration.

de Lange SM, van der Born K, Kroep JR, Jensen HA, Pfeiffer P, Cleverly A, van Groeningen CJ, Peters GJ. de Lange SM, et al. Among authors: van der born k. Eur J Clin Pharmacol. 2005 Dec;61(11):843-9. doi: 10.1007/s00228-005-0033-7. Epub 2005 Nov 10. Eur J Clin Pharmacol. 2005. PMID: 16283278 Clinical Trial.

8

Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.

Sigmond J, Honeywell RJ, Postma TJ, Dirven CM, de Lange SM, van der Born K, Laan AC, Baayen JC, Van Groeningen CJ, Bergman AM, Giaccone G, Peters GJ. Sigmond J, et al. Among authors: van der born k. Ann Oncol. 2009 Jan;20(1):182-7. doi: 10.1093/annonc/mdn543. Epub 2008 Aug 12. Ann Oncol. 2009. PMID: 18701427 Free article. Clinical Trial.

9

The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates.

Wielinga P, Hooijberg JH, Gunnarsdottir S, Kathmann I, Reid G, Zelcer N, van der Born K, de Haas M, van der Heijden I, Kaspers G, Wijnholds J, Jansen G, Peters G, Borst P. Wielinga P, et al. Among authors: van der born k. Cancer Res. 2005 May 15;65(10):4425-30. doi: 10.1158/0008-5472.CAN-04-2810. Cancer Res. 2005. PMID: 15899835

10

Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts.

Staffhorst RW, van der Born K, Erkelens CA, Hamelers IH, Peters GJ, Boven E, de Kroon AI. Staffhorst RW, et al. Among authors: van der born k. Anticancer Drugs. 2008 Aug;19(7):721-7. doi: 10.1097/CAD.0b013e328304355f. Anticancer Drugs. 2008. PMID: 18594214

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page